S
Shuimu BioSciences
Brings the power of Cryo-EM to new therapeutics developers through a differentiated service offering
About Shuimu BioSciences
Shuimu BioSciences specializes in drug discovery and structural biology using cutting-edge Cryo-Electron Microscopy (Cryo-EM) and X-ray crystallography technologies. The company serves pharmaceutical and biotechnology firms, academic institutions, and research organizations. Operating in the highly specialized market of structural biology, Shuimu BioSciences employs a business model that includes service contracts, collaborative research agreements, and licensing of proprietary technologies. Revenue is generated through fees for services rendered, milestone payments, and royalties from licensed technologies. The company's innovative platforms, such as GraFuture and Lipid Nanodiscs, enable high-resolution structural analysis, accelerating the development of novel therapeutics.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Dongcheng District, China
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Shuimu BioSciences.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Gaorong Ventures- PCPuhua Capital
Series A2 investors entered at this stage
ByteDance
China Internet Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shuimu BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shuimu BioSciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.